Recruiting

Stem Cell Transplant for Blood Disorders

Plain-English translation of NCT06872333 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing allogeneic hematopoietic stem cell transplantation (HSCT) — a procedure where healthy blood-forming stem cells from a donor are transplanted into patients with serious inherited blood disorders like sickle cell disease or thalassemia. The goal is to help these patients' bone marrow start making healthy blood cells again, reducing or eliminating their need for regular blood transfusions. The study is testing different transplant approaches depending on whether a matched sibling donor, unrelated donor, or partially matched donor is available.

Many patients with sickle cell disease, thalassemia, and related blood disorders depend on frequent blood transfusions to survive, which can lead to serious complications over time. Stem cell transplantation offers the possibility of curing these disorders by replacing the faulty blood-making cells with healthy ones, but the research team wants to find the safest and most effective ways to do this across different types of donors and patient ages.

Do you qualify?

You likely qualify if…

you have been diagnosed with sickle cell disease, thalassemia, Diamond Blackfan anemia, or another serious red blood cell disorder
you are between 0 and 55 years old (depending on the transplant type and donor availability)
you have a healthy potential donor — either a matched sibling, fully matched unrelated donor, or partially matched donor
you are in reasonably good overall health (your doctor will assess this using standard health measures)
you are willing to use effective birth control during treatment and for at least 4 months after transplant if you could become pregnant

You likely don't qualify if…

you are pregnant, breastfeeding, or planning to become pregnant during the study
you have HIV infection with a detectable viral load (though those with well-controlled HIV may be evaluated)
you have an active, uncontrolled infection at the time of enrollment
you have a known allergy to any of the medications or materials used in the transplant procedure
you have a psychiatric condition or social situation that would make it difficult for you to follow the study requirements

What participation looks like

You would receive intensive chemotherapy and other conditioning medications to prepare your bone marrow for the transplant, followed by an infusion of healthy stem cells from your donor. The exact medications and approach would depend on your age, which donor is available, and your doctor's judgment. You would need close monitoring in the hospital during the initial recovery period and frequent follow-up visits afterward to watch for complications and track how well your new bone marrow is working.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(1 site)

United States

Masonic Cancer Center, Minneapolis, Minnesota